Print Page  E-mail Page  RSS  E-mail Alerts  Tearsheet 

SEC Filings

Form 20-F
ADVANCED ACCELERATOR APPLICATIONS S.A. filed this Form 20-F on 03/29/2017
Document Outline
Entire Document (3079.5 KB)
Subdocument 1 - 20-F - FORM 20-F
Page 1 - FORM 20-F
Page 2 - Advanced Accelerator Applications S.A.
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - You should carefully consider the risks and uncertainties described below and the other information
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - N/A
Page 30 - N/A
Page 31 - N/A
Page 32 - N/A
Page 33 - inter partes
Page 34 - N/A
Page 35 - N/A
Page 36 - N/A
Page 37 - We have identified material weaknesses in our internal control over financial reporting. If the sinc
Page 38 - N/A
Page 39 - N/A
Page 40 - cr dit d imp t recherche
Page 41 - N/A
Page 42 - N/A
Page 43 - N/A
Page 44 - N/A
Page 45 - N/A
Page 46 - N/A
Page 47 - N/A
Page 48 - N/A
Page 49 - N/A
Page 50 - soci t responsabilit limit e
Page 51 - Lutetium Lu 177 dotatate (Lutathera ) an investigational innovative radiopharmaceutical for the trea
Page 52 - The New England Journal of Medicine
Page 53 - Other Nuclear Medicine Therapeutic and Diagnostic Candidates
Page 54 - N/A
Page 55 - N/A
Page 56 - Source: MEDraysintell, Nuclear Medicine. World Market Report Directory, 2016 edition
Page 57 - Agence Nationale de S curit du M dicament et des Produits de Sant
Page 58 - Source: Yao et al., One hundred years after carcinoid : epidemiology of and prognostic factors for N
Page 59 - N/A
Page 60 - Table 1: Response to treatments: Partial Response (PR)/Complete Response (CR), progression-free surv
Page 61 - N/A
Page 62 - N/A
Page 63 - Table 2: NETTER-1 population characteristics at enrollment. BMI refers to Body Mass Index.
Page 64 - Table 4: NET tumoral markers in the NETTER-1 population. Tissue markers: Synaptophysin and Chromogra
Page 65 - Table 8: Reasons for end of treatment in the NETTER-1 population.
Page 66 - Table 9: Kaplan-Meier function for Progression Free Survival in the NETTER-1 study: Final analysis.
Page 67 - Table 11: Kaplan-Meier function for Overall Survival in the NETTER-1 study: Interim analysis.
Page 68 - Table 13: Number and grading of treatment emergent adverse event episodes in patients experiencing a
Page 69 - Table 16: lutetium Lu 177 dotatate (Lutathera ) dose exposure (n=111).
Page 70 - N/A
Page 71 - N/A
Page 72 - Table 17: Objective tumor Response (CR, PR and MR) to lutetium Lu 177 dotatate (Lutathera ) by main
Page 73 - N/A
Page 74 - N/A
Page 75 - N/A
Page 76 - N/A
Page 77 - N/A
Page 78 - N/A
Page 79 - N/A
Page 80 - N/A
Page 81 - N/A
Page 82 - N/A
Page 83 - N/A
Page 84 - N/A
Page 85 - N/A
Page 86 - N/A
Page 87 - N/A
Page 88 - Phase 1
Page 89 - N/A
Page 90 - Priority Review.
Page 91 - N/A
Page 92 - N/A
Page 93 - N/A
Page 94 - N/A
Page 95 - N/A
Page 96 - N/A
Page 97 - N/A
Page 98 - N/A
Page 99 - N/A
Page 100 - N/A
Page 101 - N/A
Page 102 - soci t responsabilit limit e
Page 103 - N/A
Page 104 - The following discussion of our financial condition and results of operations should be read in conj
Page 105 - N/A
Page 106 - N/A
Page 107 - N/A
Page 108 - N/A
Page 109 - Agence Nationale de la Recherche
Page 110 - N/A
Page 111 - N/A
Page 112 - N/A
Page 113 - N/A
Page 114 - N/A
Page 115 - N/A
Page 116 - N/A
Page 117 - Banque Publique d Investissement
Page 118 - Internal Control Over Financial Reporting
Page 119 - N/A
Page 120 - N/A
Page 121 - N/A
Page 122 - N/A
Page 123 - N/A
Page 124 - N/A
Page 125 - Stefano Buono
Page 126 - Claude Hariton
Page 127 - Yvonne Greenstreet
Page 128 - Administration
Page 129 - Vesting and Holding Periods
Page 130 - soci t s anonymes
Page 131 - soci t anonyme
Page 132 - N/A
Page 133 - N/A
Page 134 - N/A
Page 135 - N/A
Page 136 - N/A
Page 137 - N/A
Page 138 - N/A
Page 139 - N/A
Page 140 - N/A
Page 141 - Quorum and Voting.
Page 142 - Approval of Dividends.
Page 143 - Repurchase and Redemption of Shares.
Page 144 - Ordinary Shareholders Meeting.
Page 145 - Increases in Share Capital.
Page 146 - Preferential Subscription Rights.
Page 147 - soci t s anonymes
Page 148 - N/A
Page 149 - N/A
Page 150 - N/A
Page 151 - N/A
Page 152 - N/A
Page 153 - N/A
Page 154 - The following summary contains a description of the material French and U.S. federal income tax cons
Page 155 - N/A
Page 156 - acte
Page 157 - N/A
Page 158 - N/A
Page 159 - de minimis
Page 160 - N/A
Page 161 - N/A
Page 162 - Fees and Expenses
Page 163 - Payment of Taxes
Page 164 - N/A
Page 165 - N/A
Page 166 - Remediation Efforts to Address Material Weaknesses
Page 167 - N/A
Page 168 - N/A
Page 169 - N/A
Page 170 - N/A
Page 171 - N/A
Page 172 - N/A
Page 173 - N/A
Page 174 - Report of Independent Registered Public Accounting Firm
Page 175 - Report of Independent Registered Public Accounting Firm on the Internal Control over Financial Repor
Page 176 - N/A
Page 177 - CONSOLIDATED STATEMENTS OF INCOME
Page 178 - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Page 179 - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Page 180 - CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
Page 181 - CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
Page 182 - CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
Page 183 - CONSOLIDATED STATEMENTS OF CASH FLOWS
Page 184 - N/A
Page 185 - N/A
Page 186 - N/A
Page 187 - Acquisition of the PetNet business in Germany
Page 188 - Acquisition of non-controlling interest in AAA Germany GmbH
Page 189 - Other development
Page 190 - Annexin
Page 191 - Group structure
Page 192 - Share-based payment
Page 193 - New currently effective requirements
Page 194 - Forthcoming requirements
Page 195 - IFRS 15
Page 196 - N/A
Page 197 - N/A
Page 198 - Goodwill
Page 199 - Internally-generated intangible assets Research development expenditure
Page 200 - Property, plant and equipment
Page 201 - Reversal of Impairment losses
Page 202 - Provision for the decommissioning of PET production sites
Page 203 - Employee benefits,
Page 204 - N/A
Page 205 - N/A
Page 206 - Operating segment
Page 207 - Non-current assets by country
Page 208 - N/A
Page 209 - N/A
Page 210 - N/A
Page 211 - N/A
Page 212 - N/A
Page 213 - Carry forward losses
Page 214 - Acquisition of the PetNet business in Germany
Page 215 - Acquisition of Imaging Equipment Ltd. (IEL)
Page 216 - Acquisition of the SteriPET business of GE Healthcare S.r.L. in Italy
Page 217 - N/A
Page 218 - N/A
Page 219 - N/A
Page 220 - N/A
Page 221 - N/A
Page 222 - N/A
Page 223 - Change in allowance for doubtful accounts
Page 224 - N/A
Page 225 - Increase of share capital in 2016
Page 226 - Increase of share capital in 2014
Page 227 - Provisions for decommissioning PET production sites
Page 228 - In France
Page 229 - Financial liabilities by category
Page 230 - Financial liabilities by type of interest rate
Page 231 - Advanced Accelerator Applications USA, Inc.
Page 232 - Sensitivity analysis
Page 233 - N/A
Page 234 - N/A
Page 235 - Risk of unsuccessful R D projects
Page 236 - Risk of emerging competitive technologies
Page 237 - Interest rate risk
Page 238 - Credit risk
Page 239 - N/A
Subdocument 2 - EX-1.1 - EXHIBIT 1.1
Page 1 - Exhibit 1.1
Page 2 - N/A
Page 3 - soci t responsabilit limit e
Page 4 - ADVANCED ACCELERATOR APPLICATIONS
Page 5 - N/A
Page 6 - ipso facto
Page 7 - ipso jure
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - d partement
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Subdocument 3 - EX-4.6 - EXHIBIT 4.6
Page 1 - Exhibit 4.6
Page 2 - N/A
Subdocument 4 - EX-4.7 - EXHIBIT 4.7
Page 1 - Exhibit 4.7
Page 2 - N/A
Subdocument 5 - EX-12.1 - EXHIBIT 12.1
Page 1 - Exhibit 12.1
Subdocument 6 - EX-12.2 - EXHIBIT 12.2
Page 1 - Exhibit 12.2
Subdocument 7 - EX-13.1 - EXHIBIT 13.1
Page 1 - Exhibit 13.1
Subdocument 8 - EX-13.2 - EXHIBIT 13.2
Page 1 - Exhibit 13.2
Subdocument 9 - EX-15.1 - EXHIBIT 15.1
Page 1 - N/A